CLAIMS

What is claimed is:

1. A compound of Formula (1):

wherein:

X is NH or O;

 R_1 is selected from the group consisting of H, halogen, hydroxy, thioxy, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, C_{2-8} dialkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-5} cycloalkyl, C_{1-4} haloalkoxy, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl;

 R_2 is selected from the group consisting of H, halogen, hydroxy, thioxy, cyano, nitro, $C_{1\cdot4}$ haloalkyl, amino, $C_{1\cdot4}$ alkylamino, $C_{2\cdot8}$ dialkylamino, $C_{1\cdot4}$ alkyl, $C_{1\cdot4}$ alkoxy, $C_{2\cdot4}$ alkenyl, $C_{2\cdot4}$ alkynyl, $C_{3\cdot5}$ cycloalkyl, $C_{1\cdot4}$ haloalkoxy, $C_{1\cdot4}$ alkylthio, $C_{1\cdot4}$ alkylsulfinyl, $C_{1\cdot4}$ alkylsulfonyl, $C_{1\cdot4}$ haloalkylsulfinyl and $C_{1\cdot4}$ haloalkylsulfonyl; or R_2 is absent;

 $\frac{---}{2}$ is a single bond when R_2 is present, or $\frac{---}{2}$ is a double bond when R_2 is absent; and

Ring A is a 5, 6 or 7-membered carbocyclic ring or a 5, 6 or 7-membered heterocyclic ring optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, hydroxy, thioxy, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, C_{2-8} dialkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-5} cycloalkyl, C_{1-4} haloalkoxy, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfinyl, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

2. The compound according to claim 1 wherein:

X is NH;

R₁ is H or hydroxy;

R₂ is H or absent;

 $\underline{\hspace{0.1cm}\text{---}}$ is a single bond when R_2 is H, or $\underline{\hspace{0.1cm}\text{---}}$ is a double bond when R_2 is absent; and

Ring A is a 5-membered carbocyclic ring or a 5-membered heterocyclic ring optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C_{1-4} alkyl, C_{1-4} alkoxy and C_{3-5} cycloalkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

3. The compound according to claim 1 having Formula (If):

wherein:

R₁ is H or hydroxy; and

Ring A is optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, C_{1-4} alkyl, C_{1-4} alkoxy and C_{3-5} cycloalkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

4. The compound according to claim 1 having Formula (Ih):

wherein:

Ring A is optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, C_{1-4} alkyl, C_{1-4} alkoxy and C_{3-5} cycloalkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

5. The compound according to claim 1 having Formula (Ih):

wherein:

Ring A is unsubstituted or is substituted with ethyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof..

6. The compound according to claim 1 having Formula (Ih):

wherein:

Ring A is substituted with 1 or 2 substituents selected from the group consisting of halogen, n-propyl, n-butyl, C_{1-4} alkoxy and C_{3-5} cycloalkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

- 7. The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 8. The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-4H-thieno[3,4-c]pyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 9. The compound according to claim 1 that is 6-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydro-4H-furo[3,4-c]pyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 10. The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 11. The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 12. The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-4H-furo[3,4-c]pyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 13. The compound according to claim 1 that is 5-Ethyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

- 14. The compound according to claim 1 that is 5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 15. The compound according to claim 1 that is 5-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydrocyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 16. The compound according to claim 1 that is 5-Methyl-3-(1H-tetrazol-5-yl)-2,4-dihydrocyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 17. The compound according to claim 1 that is 5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 18. The compound according to claim 1 that is 5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- The compound according to claim 1 that is 5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-19. tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- The compound according to claim 1 that is 5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-20. tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- The compound according to claim 1 that is 5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-21. tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- The compound according to claim 1 that is 5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-22. tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 23. The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydrocyclopentapyrazol-6-ol or a pharmaceutically acceptable salt, solvate or hydrate thereof.

79.WO1

- 24. The compound according to claim 1 that is 5-Methoxy-3-(1H-tetrazol-5-yl)-2,4,5,6tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- The compound according to claim 1 that is 5,5-Difluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-25. tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- The compound according to claim 1 that is 5-Ethoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-26. tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- A pharmaceutical composition comprising a compound according to any one of claims 1 27. to 26 in combination with a pharmaceutically acceptable carrier.
- A method of treatment of a metabolic-related disorder comprising administering to an 28. individual in need of such treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 26.
- The method according to claim 27 wherein said metabolic-related disorder is selected 29. from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
- The method according to claim 27 wherein said metabolic-related disorder is 30. atherosclerosis.
- A method of raising HDL in an individual comprising administering to said individual a 31. therapeutically-effective amount of a compound according to any one of claims 1 to 26.
- A compound according to any one of claims 1 to 26 for use in a method of treatment of 32. the human or animal body by therapy.
- A compound according to any one of claims 1 to 26 for use in a method of treatment of a 33. metabolic-related disorder of the human or animal body by therapy.
- A compound according to any one of claims 1 to 26 for use in a method of treatment of a 34. metabolic-related disorder of the human or animal body by therapy wherein said

91 79.WO1

- metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
- A compound according to any one of claims 1 to 26 for use in a method of treatment of 35. atherosclerosis of the human or animal body by therapy.
- A compound according to any one of claims 1 to 26 for use in a method of raising HDL 36. of the human or animal body by therapy.
- 37. Use of a compound according to any one of claims 1 to 26 for the manufacture of a medicament for use in the treatment of a metabolic-related disorder.
- Use of a compound according to any one of claims 1 to 26 for the manufacture of a 38. medicament for use in the treatment of a metabolic-related disorder selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
- Use of a compound according to any one of claims 1 to 26 for the manufacture of a 39. medicament for use in the treatment of atherosclerosis.
- Use of a compound according to any one of claims 1 to 26 for the manufacture of a 40. medicament for use in raising HDL in an individual.
- A method of producing a pharmaceutical composition comprising admixing a compound 41. according to any one of claims 1 to 26 and a pharmaceutically acceptable carrier.